Several other brokerages also recently weighed in on KDMN. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 target price (up previously from $8.00) on shares of Kadmon in a research report on Tuesday. Zacks Investment Research downgraded Kadmon from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $9.35.
Shares of NYSE KDMN opened at $3.69 on Wednesday. Kadmon has a 1-year low of $1.63 and a 1-year high of $3.74. The business has a 50-day moving average of $2.80 and a 200-day moving average of $2.42. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.29 and a quick ratio of 2.29. The company has a market capitalization of $390.37 million, a price-to-earnings ratio of -3.58 and a beta of 2.22.
Hedge funds and other institutional investors have recently modified their holdings of the company. Meeder Asset Management Inc. boosted its position in shares of Kadmon by 736.6% in the third quarter. Meeder Asset Management Inc. now owns 9,955 shares of the company’s stock worth $25,000 after buying an additional 8,765 shares during the period. D. E. Shaw & Co. Inc. purchased a new stake in shares of Kadmon in the second quarter worth about $27,000. Parametric Portfolio Associates LLC purchased a new stake in shares of Kadmon in the second quarter worth about $30,000. California Public Employees Retirement System purchased a new stake in shares of Kadmon in the third quarter worth about $56,000. Finally, Capital Investment Advisors LLC boosted its position in shares of Kadmon by 134.5% in the second quarter. Capital Investment Advisors LLC now owns 28,815 shares of the company’s stock worth $59,000 after buying an additional 16,525 shares during the period. 76.63% of the stock is owned by institutional investors.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Featured Story: How to read a candlestick chart
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.